Evidence map›Paper›PMID 37877816›Full record

ArticleMutagenesis2024

Matrine and Oxymatrine: evaluating the gene mutation potential using in silico tools and the bacterial reverse mutation assay (Ames test).

Benjamin Christian Fischer, Yemurai Musengi, Jeannette König, Benjamin Sachse, Stefanie Hessel-Pras, Bernd Schäfer, Carsten Kneuer, Kristin Herrmann

Open access · hybridAbstract read
In one paragraph

Article in Mutagenesis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Safety Assessment ofToxics · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Benjamin Christian FischerGerman Federal Institute for Risk Assessment, Department Pesticides Safety, 10589 Berlin, Berlin, Germany.ORCID 0000-0001-7862-5295
Yemurai MusengiGerman Federal Institute for Risk Assessment, Department Pesticides Safety, 10589 Berlin, Berlin, Germany.
Jeannette KönigGerman Federal Institute for Risk Assessment, Department Pesticides Safety, 10589 Berlin, Berlin, Germany.
Benjamin SachseGerman Federal Institute for Risk Assessment, Department Food Safety, 10589 Berlin, Berlin, Germany.
Stefanie Hessel-PrasGerman Federal Institute for Risk Assessment, Department Food Safety, 10589 Berlin, Berlin, Germany.
Bernd SchäferGerman Federal Institute for Risk Assessment, Department Food Safety, 10589 Berlin, Berlin, Germany.
Carsten KneuerGerman Federal Institute for Risk Assessment, Department Pesticides Safety, 10589 Berlin, Berlin, Germany.
Kristin HerrmannGerman Federal Institute for Risk Assessment, Department Pesticides Safety, 10589 Berlin, Berlin, Germany.
Federal Institute for Risk Assessment · DE

Funding

BfR internal research 1322-804
6 · The paper itself

Abstract

The quinolizidine alkaloids matrine and its N-oxide oxymatrine occur in plants of the genus Sophora. Recently, matrine was sporadically detected in liquorice products. Morphological similarity of the liquorice plant Glycyrrhiza glabra with Sophora species and resulting confusion during harvesting may explain this contamination, but use of matrine as pesticide has also been reported. The detection of matrine in liquorice products raised concern as some studies suggested a genotoxic activity of matrine and oxymatrine. However, these studies are fraught with uncertainties, putting the reliability and robustness into question. Another issue was that Sophora root extracts were usually tested instead of pure matrine and oxymatrine. The aim of this work was therefore to determine whether matrine and oxymatrine have potential for causing gene mutations. In a first step and to support a weight-of-evidence analysis, in silico predictions were performed to improve the database using expert and statistical systems by VEGA, Leadscope (Instem®), and Nexus (Lhasa Limited). Unfortunately, the confidence levels of the predictions were insufficient to either identify or exclude a mutagenic potential. Thus, in order to obtain reliable results, the bacterial reverse mutation assay (Ames test) was carried out in accordance with OECD Test Guideline 471. The test set included the plate incorporation and the preincubation assay. It was performed with five different bacterial strains in the presence or absence of metabolic activation. Neither matrine nor oxymatrine induced a significant increase in the number of revertants under any of the selected experimental conditions. Overall, it can be concluded that matrine and oxymatrine are unlikely to have a gene mutation potential. Any positive findings with Sophora extracts in the Ames test may be related to other components. Notably, the results also indicated a need to extend the application domain of respective (Q)SAR tools to secondary plant metabolites.

Indexed as

AlkaloidsSophoraMatrinesMutationQuinolizinesReproducibility of ResultsAlkaloidsMatrinesoxymatrineQuinolizinesAmes testin silicoliquoricematrinemutagenicityoxymatrineQSAR

Identifiers

PMID37877816
PMCPMC10851102
OpenAlexW4387931577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.